| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy;
HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and
GSF-National Research Center for Environment and Health GmbH, Institute for Molecular Virology, Neuherberg, Germany
Kaposi’s sarcoma (KS) is an angioproliferative disease characterized by proliferation of spindle-shaped cells predominantly of endothelial cell origin, neoangiogenesis, inflammatory cell infiltration, and edema. At least in early stage, KS behaves as a reactive lesion sustained by the action of inflammatory cytokines and growth factors, has a polyclonal nature, and can regress. However, in time it can become monoclonal, especially in the nodular stage, evolving into a true sarcoma, likely in association with the increased expression of antiapoptotic oncogenes. We have recently demonstrated by immunohistochemical analysis that Bcl-2, a proto-oncogene known to prolong cellular viability and to antagonize apoptosis, is highly expressed in spindle cells and vessels of both AIDS-KS and classical KS lesions and that its expression increases with lesion stage. Paclitaxel, a microtubule-stabilizing drug known to inhibit Bcl-2 antiapoptotic activity and to be highly effective in the treatment of certain neoplasms, has recently been found to be active also in patients with advanced HIV-associated KS. In this report we investigated the mechanism(s) of paclitaxel activity in KS. By using a model of experimental KS induced by the inoculation of KS-derived spindle cells in nude mice and primary cultures of KS spindle cells, we found that paclitaxel promotes regression of KS lesions in vivo and that it blocks the growth, migration, and invasion of KS cells in vitro. Furthermore, paclitaxel treatment promoted apoptosis and down-regulated Bcl-2 protein expression in KS cells in vitro and in KS-like lesions in mice. Our results suggest that paclitaxel interferes with KS by down-regulating Bcl-2 antiapoptotic effect.
This article has been cited by other articles:
|
|
 |
|
  A. D.-A. Tran, T. P. Marmo, A. A. Salam, S. Che, E. Finkelstein, R. Kabarriti, H. S. Xenias, R. Mazitschek, C. Hubbert, Y. Kawaguchi, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions J. Cell Sci., April 15, 2007; 120(8): 1469 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gambassi, R. Semeraro, V. Suma, A. Sebastio, and R. Antonelli Incalzi Aggressive Behavior of Classical Kaposi's Sarcoma and Coexistence With Angiosarcoma J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2005; 60(4): 520 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stebbing, A. Wildfire, S. Portsmouth, T. Powles, C. Thirlwell, P. Hewitt, M. Nelson, S. Patterson, S. Mandalia, F. Gotch, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations Ann. Onc., November 1, 2003; 14(11): 1660 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Lane, J. Liu, P. J. Bock, D. Schols, M. J. Coffey, R. M. Strieter, P. J. Polverini, and D. M. Markovitz Interleukin-8 and Growth-Regulated Oncogene Alpha Mediate Angiogenesis in Kaposi's Sarcoma J. Virol., October 11, 2002; 76(22): 11570 - 11583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Walker, S. Fujisaki, R. Long, and R. Croteau Molecular cloning and heterologous expression of the C-13 phenylpropanoid side chain-CoA acyltransferase that functions in Taxol biosynthesis PNAS, October 1, 2002; 99(20): 12715 - 12720. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
